MedTrace Logo

Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis

NCT04857489 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2022-06-15

No results posted yet for this study

Summary

The purpose of this research is to find out how the T regulatory (Treg) cells control autoimmune response in multiple sclerosis. The investigators will identify Treg molecular markers and changes in function in patients with relapse remitting multiple sclerosis (RRMS). The investigators plan to study T regulatory immune cells in the blood of RRMS patients and control subjects to examine how Treg immune cells' deficient function may be involved in the development of mulitple sclerosis.

Conditions

  • Relapse Remitting Multiple Sclerosis

Sponsors & Collaborators

  • Thomas Jefferson University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04857489 on ClinicalTrials.gov